Join        Login             Stock Quote

Novo Nordisk (NVO) Retreats Sharply After FDA Letter

 February 11, 2013 07:36 AM

(By Balachander) Novo Nordisk (NYSE: NVO) said the U.S. health regulators would not approve the Denmark-based drug maker's new drug applications (NDA) for insulin Tresiba and Ryzodeg.

American depositary receipts (ADRs) of NVO plunged 12.26 percent in premarket trading on Monday.

In a Complete Response Letter, the US Food and Drug Administration (FDA) requests additional cardiovascular data from a dedicated cardiovascular outcomes trial before the review of the NDAs can be completed.

Novo Nordisk said it does not expect to be able to provide the requested data during 2013.

The company said it was evaluating the content of the Complete Response Letter and will work closely with the FDA to provide the requested data.

[Related -Novo Nordisk A/S (ADR) (NVO): A Company Solving The Global Diabetes Crisis Is A 'Buy']

The NDAs for Tresiba and Ryzodeg were submitted by the company to the FDA in September 2011.

Tresiba and Ryzodeg are approved in Japan, the EU and Mexico and under regulatory review in a number of countries throughout the world.

ADRs have been trading in the 52-week range of $129.41 to $194.44.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageWatch This Alternative Investment for a Buy Signal

All major U.S. indices closed essentially unchanged last week except for the small-cap Russell 2000. While read on...

article imageUS REITs Edged Higher Last Week As Emerging Markets Slumped

Real estate investment trusts (REITs) in the US took the lead in last week’s shortened holiday trading week read on...

article imageA Contrarian Perspective On The Short EuroTtrade

As the euro continues to drift lower, it has become the accepted wisdom that we are headed for parity with read on...

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.